The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting

201772 citationsJournal Articlegold Open Access

Authors

I-SPY 2 TRIAL beginning December 31, 2009: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (I-SPY 2), NCT01042379 .

Good health and well-being

Published in: Breast Cancer Research

Volume 19, Issue 1, pp. 99-99

Field-Weighted Citation Impact: 7.06